Pharmaceutical Manufacturing of Milbemycin Oxime

This contract involves the manufacturing of Milbemycin Oxime, a veterinary antiparasitic agent, encompassing the complete process from synthesis and purification to initial packaging. The work must be conducted in compliance with current Good Manufacturing Practices (cGMP) and FDA regulations, ensuring the highest quality standards for pharmaceutical production. The contract is positioned as a subcontract opportunity under the Department of Defense through the Medical Supply Chain Pharm FSA and is identified with NAICS code 325412, which pertains to pharmaceutical manufacturing. The place of performance for this contract is specified as APO, with the ZIP code 09227-0000, indicating a location supporting military or overseas operations. The solicitation was posted on May 27, 2026, with a response deadline of June 2, 2026, providing a limited window for interested parties to submit their proposals. There is no designated small business set-aside, allowing all eligible manufacturers to compete. This contract emphasizes stringent regulatory adherence and is geared toward ensuring a reliable supply of veterinary pharmaceuticals within a defense-related supply chain context.